File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: mTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers

TitlemTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers
Authors
Issue Date2017
PublisherOxford University Press (OUP): Policy C - Option B. The Journal's web site is located at http://nar.oxfordjournals.org/
Citation
Nucleic Acids Research, 2017, v. 45 n. W1, p. W215-W221 How to Cite?
AbstractCancer therapies have experienced rapid progress in recent years, with a number of novel small-molecule kinase inhibitors and monoclonal antibodies now being widely used to treat various types of human cancers. During cancer treatments, mutations can have important effects on drug sensitivity. However, the relationship between tumor genomic profiles and the effectiveness of cancer drugs remains elusive. We introduce Mutation To Cancer Therapy Scan (mTCTScan) web server (http://jjwanglab.org/mTCTScan) that can systematically analyze mutations affecting cancer drug sensitivity based on individual genomic profiles. The platform was developed by leveraging the latest knowledge on mutation-cancer drug sensitivity associations and the results from large-scale chemical screening using human cancer cell lines. Using an evidence-based scoring scheme based on current integrative evidences, mTCTScan is able to prioritize mutations according to their associations with cancer drugs and preclinical compounds. It can also show related drugs/compounds with sensitivity classification by considering the context of the entire genomic profile. In addition, mTCTScan incorporates comprehensive filtering functions and cancer-related annotations to better interpret mutation effects and their association with cancer drugs. This platform will greatly benefit both researchers and clinicians for interrogating mechanisms of mutation-dependent drug response, which will have a significant impact on cancer precision medicine.
Persistent Identifierhttp://hdl.handle.net/10722/242938
ISSN
2023 Impact Factor: 16.6
2023 SCImago Journal Rankings: 7.048
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, J-
dc.contributor.authorYao, H-
dc.contributor.authorHuang, D-
dc.contributor.authorLiu, H-
dc.contributor.authorLiu, Z-
dc.contributor.authorXu, H-
dc.contributor.authorQin, Y-
dc.contributor.authorPrinz, J-
dc.contributor.authorXia, W-
dc.contributor.authorWang, P-
dc.contributor.authorYan, B-
dc.contributor.authorTran, NL-
dc.contributor.authorKocher, JP-
dc.contributor.authorSham, PC-
dc.contributor.authorWang, JJ-
dc.date.accessioned2017-08-25T02:47:35Z-
dc.date.available2017-08-25T02:47:35Z-
dc.date.issued2017-
dc.identifier.citationNucleic Acids Research, 2017, v. 45 n. W1, p. W215-W221-
dc.identifier.issn0305-1048-
dc.identifier.urihttp://hdl.handle.net/10722/242938-
dc.description.abstractCancer therapies have experienced rapid progress in recent years, with a number of novel small-molecule kinase inhibitors and monoclonal antibodies now being widely used to treat various types of human cancers. During cancer treatments, mutations can have important effects on drug sensitivity. However, the relationship between tumor genomic profiles and the effectiveness of cancer drugs remains elusive. We introduce Mutation To Cancer Therapy Scan (mTCTScan) web server (http://jjwanglab.org/mTCTScan) that can systematically analyze mutations affecting cancer drug sensitivity based on individual genomic profiles. The platform was developed by leveraging the latest knowledge on mutation-cancer drug sensitivity associations and the results from large-scale chemical screening using human cancer cell lines. Using an evidence-based scoring scheme based on current integrative evidences, mTCTScan is able to prioritize mutations according to their associations with cancer drugs and preclinical compounds. It can also show related drugs/compounds with sensitivity classification by considering the context of the entire genomic profile. In addition, mTCTScan incorporates comprehensive filtering functions and cancer-related annotations to better interpret mutation effects and their association with cancer drugs. This platform will greatly benefit both researchers and clinicians for interrogating mechanisms of mutation-dependent drug response, which will have a significant impact on cancer precision medicine.-
dc.languageeng-
dc.publisherOxford University Press (OUP): Policy C - Option B. The Journal's web site is located at http://nar.oxfordjournals.org/-
dc.relation.ispartofNucleic Acids Research-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlemTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers-
dc.typeArticle-
dc.identifier.emailLi, J: mulin@hku.hk-
dc.identifier.emailYan, B: yanbin14@hku.hk-
dc.identifier.emailSham, PC: pcsham@hku.hk-
dc.identifier.authorityYan, B=rp01940-
dc.identifier.authoritySham, PC=rp00459-
dc.identifier.authorityWang, JJ=rp00280-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1093/nar/gkx400-
dc.identifier.scopuseid_2-s2.0-85023175603-
dc.identifier.hkuros275268-
dc.identifier.volume45-
dc.identifier.issueW1-
dc.identifier.spageW215-
dc.identifier.epageW221-
dc.identifier.isiWOS:000404427000031-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0305-1048-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats